Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy

  title={Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy},
  author={P. Richardson and C. Mitsiades and J. Laubach and R. Schlossman and I. Ghobrial and T. Hideshima and N. Munshi and K. Anderson},
  journal={Core evidence},
  pages={215 - 245}
  • P. Richardson, C. Mitsiades, +5 authors K. Anderson
  • Published 2010
  • Medicine
  • Core evidence
  • Introduction: Multiple myeloma (MM) is a relatively common and incurable hematological malignancy. Currently, there is no single standard therapy, with choice of treatment dependent on individual patient factors. Lenalidomide is an immunomodulatory drug with potent antitumor, antiangiogenic, immunomodulatory, and proapoptotic activity in MM. Aims: To evaluate the evidence for the use of lenalidomide in its current indication in relapsed or refractory MM, and additionally its investigational use… CONTINUE READING
    17 Citations
    Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea
    • 3
    • PDF
    Targeting Multiple Myeloma Tumor Angiogenesis: Focus on VEGF
    Rapid in vivo testing of drug response in multiple myeloma made possible by xenograft to turkey embryos
    • 5
    • PDF


    Treatment of myeloma in patients not eligible for transplantation
    • S. Jagannath
    • Medicine
    • Current treatment options in oncology
    • 2005
    • 13
    Thalidomide and lenalidomide in the treatment of multiple myeloma.
    • 107
    • Highly Influential
    Thalidomide and dexamethasone: therapy for multiple myeloma
    • 21
    Initial therapy of multiple myeloma patients who are not candidates for stem cell transplantation.
    • R. Orlowski
    • Medicine
    • Hematology. American Society of Hematology. Education Program
    • 2006
    • 13
    • PDF
    Emerging role of novel combinations for induction therapy in multiple myeloma.
    • 6
    Maintenance therapy in multiple myeloma
    • 30
    • PDF
    New drugs for myeloma.
    • 165
    Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients
    • 94